INTRODUCTION
Respiratory syncytial virus (RSV) is the leading cause of morbidity from lower respiratory tract viral infection in infants and children age o5 years. 1 There is as yet no RSV vaccine, and while a number of candidates are in late stages of clinical trials, the ideal immune correlates of protection are not fully characterized. The main target of vaccine-induced adaptive immunity has traditionally been antibody. Antibody is a key correlate of protection against RSV, for example, maternal antibody levels closely correlate with the risk of RSV infection in the infant. 2 But protection can occur in the absence of detectable serum antibodies, 3 and infection can occur when serum-neutralizing antibodies are high. 4 This suggests a role for protective T-cell immunity, supported by the observation that children with defective T-cell responses were unable to clear the virus for several months and suffered from more severe disease. 5 Their protective capacity should make the induction of CD8 T cells an attractive goal for an RSV vaccine; and yet, there is a substantial body of evidence suggesting that excess T-cell responses can be detrimental. [6] [7] [8] One possibility is that the wrong types of T cells, either functionally or spatially, are being induced. Memory T cells can be phenotypically characterized by their cell surface marker expression, with different subsets behaving differently on re-exposure to the pathogen. 9 Recently, a novel population of tissue resident memory T (Trm) cells has been defined. These cells move from the circulation to the tissues, leading to the upregulation of CD69, the downregulation of S1P1, and normally the upregulation of the integrin CD103, which leads to their retention in the tissue. 10 Functionally, these cells are primed to respond more rapidly to pathogen, with 20 times higher affinity for antigen than effector memory T cells, allowing them to detect cells expressing low levels of antigen, such as those in the early stages of infection. 11 Once a pathogen is detected, Trm cells contribute to the early immune response by secreting cytokines such as interferon gamma (IFNg) 12 ; for example, influenza-specific lung-resident T cells respond rapidly upon reactivation, producing multiple cytokines. 13 It has recently been shown that the presence of RSV-specific CD8 þ T cells in the lungs, but not the blood, of human adults correlates with less severe disease upon RSV challenge infection. 14 Less research has been performed on 
CD4
þ Trm in the lungs, but they have been shown to have a protective role in influenza 15 and Nippostrongylus brasiliensis. 16 The aim of this study was to investigate the functional role of Trm in protection against RSV infection. We demonstrate for the first time that transferring airway CD4 or CD8 cells is sufficient to protect against disease after RSV infection. We then compared the effect of memory CD8 cells generated after lung infection or systemic vaccination and saw that systemic DNA vaccines induce pathogenic but not protective CD8 T cells. Comparing vaccination and infection, we see significant differences in the localization and type of antigen-specific CD8 cells, which may contribute to their different effects. From this, we conclude that airway-resident T cells are sufficient to protect against RSV and their induction should be a goal of vaccination.
RESULTS
Prior RSV infection protects against subsequent infection and induces both RSV-specific antibody and CD8 T cells Intranasal (i.n.) infection with wild-type RSV protects against subsequent exposures 17 and antibody has a role in this protection, but the role of T cells is unclear. The aim of the study was to investigate the role of lung-resident T cells in protection against RSV infection. The response to RSV was compared after one, two, or three exposures to RSV, each 21 days apart. As expected, mice infected for the first time with RSV lost significantly more weight (Figure 1a) , had more viral load on day 4 after infection ( Figure 1b) , and significantly lower anti-RSV immunoglobulin G (IgG) in serum after infection (Figure 1c) . To distinguish between circulating and local cells, mice were pretreated with intravenous antibody prior collecting organs. CD8 T cells were recruited into both the lungs ( Figure 1d ) and airways (Figure 1e ), peaking at day 8 of mice infected with RSV for the first time. There were significantly more total CD8 cells in the lungs or bronchoalveolar lavage after a single infection than after two or three infections. However, the proportion of CD8 cells that were Trm cells (defined as CD69 þ and CD103 þ ) was significantly greater in the lungs (Figure 1f ) and airways ( Figure 1g ) of mice previously exposed to RSV than primary infection at days 4 and 8 after infection. This combination of markers has been used to identify Trm after viral infection in both human 14 and murine studies, 18 though it may also pick up some effector cells at the acute time points. Interestingly, the proportion of CD69 þ /CD103 þ cells was the same 21 days after the first, second or third exposure to RSV-rising to approximately 10% of CD8 cells after one exposure or contracting to the same proportion after two or three exposures. Of the CD69 þ /CD103 þ CD8 Trm cells, a high proportion were specific for the immunodominant peptide of the RSV M protein (Figure 1h,i) . The proportion that was pentamer positive were significantly greater after re-exposure to RSV. There were no differences seen in the response after the second or third exposure to RSV. Therefore, RSV-specific Trm are induced in the lungs and airways after infection.
Airway cell transfer reduces disease after RSV infection
The aim of the study was to define the role of airway cells in protection against RSV disease. Mice were infected with RSV, and 4 weeks later, T cells were depleted with antibody prior to reinfection with RSV. Depleting CD8 þ or CD4 þ led to a significant increase in early weight loss compared with the RSV-RSV group, indicating that they have a role in the reduction of disease (Figure 2a) . However, these mice had anti-RSV antibody that may mask any protective effect of T cells. We used transfer studies to test cells in isolation. Donor mice were infected two times with RSV or sham infected with phosphatebuffered saline (PBS); 3 weeks after the second infection, mice were culled and cells were collected from the airways or spleens. In all, 10 6 cells were instilled into the airways of naïve animals, of these 22% were lymphocytes, and of the CD8 T cells transferred, 25% were RSV-specific Trm accounting for 10 4 cells transferred (see Supplementary Figure S1 online). One day after cell transfer, recipient animals were infected with RSV. Mice receiving cells from the airways of RSV exposed animals lost significantly less weight on days 6 and 7 compared with mice receiving splenocytes from RSV-exposed animals or cells from either the airways or spleens of PBS-treated animals ( Figure 2b ). There were significantly more CD8 (Figure 2c ) and CD4 (Figure 2d ) Trm in mice receiving cells from the airways of RSV-infected animals, 7 days after infection of the recipient mice. To determine the fate of transferred airway cells from naïve or RSV infected, they were labeled with cell trace violet prior to i.n. transfer into naïve animals. Recipient mice were infected with RSV 1 day after cell transfer and then culled 2 days after RSV infection. Labeled cells were detectable at a low frequency in the airways of all mice, with significantly more cells in the airways of RSV-infected animals receiving cells from RSV donors (see Supplementary Figure S1D ).
To determine the relative contribution of CD4 and CD8 cells in protection against disease following RSV infection, airway cells from previously RSV-infected mice were sorted prior to i.n. transfer to naïve mice (see Supplementary Figure S2 ). Both CD4 and CD8 cell transfer reduced weight loss compared with control mice (Figure 2e ). There were, however, phenotypic differences between mice receiving CD4 or CD8 cells. Mice that received CD8 cells had significantly lower viral load on day 4 of infection with RSV (Po0.01, Figure 2f ) and significantly greater IFNg in the airways on day 1 of infection (Po0.01, Figure 2g ). Strikingly, transfer of CD4 þ cells led to a significant reduction in airway tumor necrosis factor alpha (TNFa) (Po0.05, Figure 2h ), but no effect on IFNg or viral load. Transferring sorted cells from the airways of PBS-exposed animals had no protective effect ( Figure 2i) . Curiously, transfer of unsorted cells from the airways of RSV-infected mice also reduced weight loss but without an impact on viral load, IFNg, or TNF. From this, we conclude that airway CD8 are protective against reinfection and airway CD4 can reduce disease.
Vaccines inducing systemic T cells do not protect against RSV infection
Having observed that T-cell transfer reduced disease after RSV infection, we wished to test whether vaccination could induce T-cell-mediated protection. DNA vaccines have been shown to induce strong cellular responses in the systemic compartment 19 and so we used them to test whether vaccine induced anti-RSV T cells could protect against RSV disease in mice. Mice were immunized intramuscularly with 5 mg plasmid encoding RSV M2 in a prime boost-boost regime. Three weeks after the second immunization, mice were infected with RSV. RSV M2-immunized mice lost more weight, more rapidly than untreated mice ( Figure 3a) . DNA immunization reduced the viral load at day 4 after infection but not to the same magnitude as previous infection with RSV ( Figure 3b ). Immunization with RSV M2 induced a significant population of RSV M2-specific CD8 cells; this was greater than in animals previously infected with RSV ( Figure 3c ). But DNA vaccination induced significantly fewer RSV-specific CD8 cells expressing Trm markers (Figure 3d ). The DNA vaccine-induced RSV-specific cells were highly inflammatory, producing significantly more TNFa (Figure 3e ) or IFNg ( Figure 3f ) than cells from naïve or previously exposed mice. It has been previously been demonstrated that excess CD8 cells in the airways can lead to enhanced disease in RSV. 6, 8 We wished to determine whether DNA vaccine-induced T cells were causing disease. When CD8 cells were depleted using antibody during RSV infection in spite of an increase of viral load (Figure 3g ), there was a significant reduction in weight loss ( Figure 3h ). From this, we conclude that systemically induced T cells can cause disease rather than protect.
Immunization and infection induce different antigen-specific T cell populations in different tissues
During infection, the proportion of airway CD8 T cells specific for the immunodominant M2 epitope was similar between RSV-infected and DNA-vaccinated animals, but there were significant differences in the proportion of those that expressed the Trm markers CD69 and CD103. To determine whether these differences occurred at the time of initial exposure to RSV antigens and whether there were differences in the cellular distribution, we compared PBS-immunized, RSV-infected and M2 DNA-immunized animals. Mice receiving DNA were immunized three times at 2-week intervals in the left anterior tibialis muscle in the hind limb. There were some differences in timing between exposure and recovery of cells: PBS or RSV groups were culled 7 weeks after the initial exposure, and DNAvaccinated mice were culled 3 weeks after the final exposure; all animals were culled and the samples were analyzed at the same time.
The phenotype of CD8 cells in the site of immunization (the left hind limb muscle and covering skin) was compared with the distal, right hind limb muscle and skin, airways, lung, blood, and spleen. No RSV-specific CD8 cells were detected after PBS delivery (Figure 4a) . RSV infection led to populations of RSVspecific cells in all tissue compartments (right muscle was not measured owing to technical complications). DNA vaccination with a plasmid encoding the M2 gene induced a population of M2-specific CD8 cells in the immunized muscle (left) but not the distal, right muscle. DNA immunization induced a larger population of RSV-specific cells in the blood and lungs than the airways or spleen. RSV-specific cells in the lungs after vaccination may represent blood contamination because the lungs were not flushed prior to analysis. RSV infection induced a population of RSV-specific CD8 T cells in all tissues assessed. Strikingly, infection induced significantly more RSV-specific CD8 Trm cells in the lungs and skin sections than DNA vaccination (Figure 4b) . Therefore, infection and immunization induce qualitatively different cell populations recognizing the same epitope, with only infection leading to the induction of a protective CD8 T-cell subset in the lungs. þ resident memory T (Trm) cells in the airways of recipient mice 7 days after RSV infection. Cells were sorted from airways of RSV-exposed mice prior to infection RSV. (e) Weight loss, (f) lung viral load at day 4 after RSV infection, (g) interferon gamma (IFNg) and (h) tumor necrosis factor alpha (TNFa) levels in the airways 1 day in recipient mice after infection. (i) Cells from PBS-exposed mice were sorted and transferred into mice before infection and weight loss. Points and bars represent n ¼ 5 animals ± s.e.m. and *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001 as measured via one-way analysis of variance (ANOVA) with Tukey's multiple comparison post test. Weight loss significance was calculated by two-way ANOVA: for a significance is shown between RSVx2 and anti-CD4 (*) or anti-CD8 (#); for b significance is shown between RSV brocheoalveolar lavage (BAL) and control (*); for e significance is shown between control and CD4 (#) or CD8 (*).
DISCUSSION
In the current study, we demonstrate for the first time that airway T cells are sufficient to protect against infection, even in the absence of antibody. Transferring CD8 T cells from mice previously infected with RSV to naïve animals reduced weight loss and viral load on exposure to RSV. This is an important finding because of the implication it has for RSV vaccine strategies. It ties in closely with a recent study which demonstrated that i.n. vaccination with a recombinant virus expressing RSV proteins was protective against infection and induced RSV-specific tissue Trm cells. 20 However, caution needs to be taken with T-cell-targeting vaccines for RSV because the induction of CD8 T cells in the systemic compartment led to enhanced disease on exposure to RSV infection.
The transfer studies demonstrate that cells resident in the airways are protective against RSV infection. Functionally, there was an increase in IFNg in the airways after CD8 transfer, which may lead to the recruitment of other antiviral cells to the airway, though the CD8 cells themselves may be having a direct antiviral effect. It was of note that transferring CD4 T cells from the airways reduced disease, without affecting viral load. There was a reduction in TNFa levels following CD4 T-cell transfer; we have previously shown that blocking TNFa reduces disease 21 and it may be that some of the CD4 cells transferred are regulatory T cells as we have shown that Treg depletion increases TNFa levels and disease. 22 Total cell transfer reduced weight loss more than either cell alone, so either T cells are working in concert or there is a role for other cell types in the airways, for example, macrophages. Macrophages make up the majority of airway cells even after RSV infection and the transferred macrophages may also release cytokines locally and promote antiviral responses. 23 Splitting the cells into different subsets prior to transfer would enable the identification of which memory or effector T cells are protective.
One of the striking findings was that, after infection, RSVspecific T cells were detectable in all tissues sampled. After infection, cells from the lungs or the skin had a greater propotion of CD69 þ /CD103 þ cells. The skin is a known site for tissue-resident cells, 24 and it may be that effector cells induced in the lungs track to other tissues where they take on the characteristics of resident memory cells. It was of note that although RSV infection induces antigen-specific cells in the spleen, transferring splenocytes was not protective: a similar phenomenon was seen when protection was transferred with airway cells but not splenocytes from influenza-infected mice. 15, 25 It will be important to determine the factors that lead to the induction of Trm in the lungs and to determine whether these can be replicated artificially for vaccine strategies. In the skin, the cytokines transforming growth factor-b and interleukin-15 are required for Trm development, 26 but their role in lung Trm formation is not known.
One approach that has promise for the induction of resident memory cells is mucosal vaccination. It was striking that intramuscular DNA vaccination, while it did induce antigenspecific cells in the immunized tissue and the blood, did not induce tissue-resident memory cells in any site tested, even the site of immunization. Route has a significant effect on the qualitative response to DNA vaccination. 27 Intranasal immunization with influenza DNA in a 100 ml volume also led to the induction of airway-resident memory cells. 28 Likewise, in a recent study, i.n. delivery of a recombinant viral vector expressing RSV M led to the induction of tissue-resident RSV-specific cells but only when delivered in a large enough volume to reach the lungs (100 ml); intraperitoneal immunization with the same vaccine did not induce Trm. 20 These studies suggest that the vaccine needs to get into the lungs to induce the correct type of memory cells and that responses in the upper airway are not the same as the lower airway. Vaccination at other mucosal sites can also lead to the induction of Trm, intravaginal immunization with human papillomavirus vectors expressing RSV antigen led to the induction of RSV specific Trm in the vagina, but when the same antigen was delivered intramuscularly, Trm were not induced. 29 One potential strategy is to induce the formation of memory CD8
þ T cells in circulation that can then be 'pulled' to a local site 30 ; however, we had limited success using this strategy to recruit antigen-specific B cells to the mucosa. 31 Ultimately, an RSV vaccine needs to be effective in early life, when the bulk of severe disease happens. The infant immune response, in particular the cellular response, is different from that of adult immune response. We have previously shown that neonatal RSV infection primes for a immunopathogenic CD8 response, 6 ,32 similar to the phenotype seen after DNA vaccination. How the immune environment in the neonatal lung differs from the adult lung with regards to the priming of T-cell responses is an important research topic for the development of optimum vaccines. Although RSV vaccines that are closest to the clinic are being developed for pregnant women with a view of passing on passive humoral immunity to the newborn, 33 based on the data presented here, we would also advocate strategies that induce local T cells.
METHODS
Mouse immunization and infection. Six-to-8-week-old female BALB/ c mice were obtained from Harlan UK (Oxford, UK) and kept in specific-pathogen-free conditions in accordance with the United Kingdom's Home Office guidelines. All work was approved by the Animal Welfare and Ethical Review Board at Imperial College London. RSV A2 virus were grown using the human laryngeal carcinoma cell line, HEp-2. Viral titer was calculated by an immuno-plaque assay using biotinylated goat anti-RSV polyclonal antibody (AbD Serotec, Oxford, UK) to detect plaques. For infections, mice were anesthetized using isoflurane and infected i.n. with 10 5 plaque-forming units RSV A2 in 100 ml. For DNA vaccination, mice were injected 5 mg plasmid DNA expressing the M2-1 gene in 20 ml intramuscularly into the left anterior tibialis muscle. Mice were DNA immunized three times, 2 weeks apart. In some studies, to distinguish between circulating and tissue-resident cells, mice were pretreated intravenously with 3 mg anti-CD45.2 (A700 fluorophore) in 200 ml 3 min prior to killing. 34 RSV viral load. Viral load in vivo was assessed by extracting RNA from frozen lung tissue disrupted in a TissueLyzer (Qiagen, Manchester, UK) using Trizol extraction and then converting it into cDNA. Quantitative reverse transcriptase-PCR was carried out using bulk viral RNA for the RSV L gene and mRNA using 900 nM forward primer (5 0 -GAACTCAGTGTAGGTAGAATGTTTGCA-3 0 ), 300 nM reverse primer (5 0 -TTCAGCTATCATTTTCTCTGCCAAT-3 0 ) and 100 nM probe (5 0 -FAM-TTTGAACCTGTCTGAACAT-TAMRA-3 0 ) on a Stratagene Mx3005p (Agilent Technologies, Santa Clara, CA). L-specific RNA copy number was determined using a RSV L gene standard.
Semiquantitative antigen-specific enzyme-linked immunosorbent assay. Antibodies specific to RSV were measured in sera using a standardized enzyme-linked immunosorbent assay. 35 MaxiSorp 96-well plates (Nunc, Thermo Scientific, Hemel Hempstead, UK) were coated with 1 mg ml À 1 RSV lysate or a combination of anti-murine lambda and kappa light-chain-specific antibodies (AbDSerotec, Oxford, UK) and incubated overnight at 4 1C. Plates were blocked with 1% bovine serum albumin in PBS. Bound IgG was detected using horseradish peroxidase-conjugated goat anti-mouse IgG (AbD Serotec). A dilution series of recombinant murine IgG was used as a standard to quantify specific antibodies. Tetramethylbenzidine with H 2 SO 4 as stop solution was used to detect the response, and optical densities were read at 450 nm.
Cell isolation
Lungs, airway cells and spleen. Mice were culled using 100 ml intraperitoneal pentobarbitone (20 mg dose, Pentoject, Animalcare, York, UK). Spleens, lung tissue and bronchoalveolar lavage were collected as previously described. 36 Lungs and spleens were homogenized by passage through 100-mm cell strainers, then centrifuged at 200 g for 5 min. Supernatants were removed and the cell pellet was treated with red blood cell lysis buffer (ACK; 0.15 M ammonium chloride, 1 M potassium hydrogen carbonate, and 0.01 mM EDTA, pH 7.2) before centrifugation at 200 g for 5 min. The remaining cells were resuspended in RPMI 1640 medium with 10% fetal calf serum, and viable cell numbers were determined by trypan blue exclusion.
Blood. For antibody-specified time points after immunization, blood samples were taken by tail vein bleed and sera were isolated after clotting by centrifugation. For cell isolation, blood was collected in heparinized capillary tubes (Hirschmann Laborgeräte, Eberstadt, Germany), followed by ACK lysis.
Skin and muscle recovery. Killed mice had both their legs shaved with electric clippers. A 2-cm 2 area of skin over each of the anterior tibialis muscles was excised and placed in a well containing Dulbecco's modified Eagle's medium þ 10% fetal calf serum (D10) in a 12-well plate kept on ice. The anterior tibialis muscles were also excised. Skin and muscle samples were chopped up into 3 mm 3 sections. One milliliter of the digestion cocktail containing 12.5 mg ml À 1 Liberase TL in SF media, DNAse at 200 mg ml À 1 , and hyaluronidase at 50 mg ml
was added to each sample as described previously. 37 Samples were placed in a shaking block at 37 1C for 1 h and then the digested sample was filtered through a 70-mm cell strainer and centrifuged at 528 g for 5 min. The supernatant was discarded and the cell pellet was resuspended in 5 ml ACK lysis buffer for 5 min. Also, 1.5 Â volume D10 was added and cells were again centrifuged at 528 g for 5 min.
Airway cell transfer. Cells were collected from the bronchoalveolar lavage or spleen, washed, and resuspended in sterile PBS. Mice were anesthetized and 10 6 cells in 100 ml were delivered i.n. with a Gilson pipette (Dunstable, UK). Isolated cells from the airways were negatively sorted for CD4 þ and CD8 þ populations using the MACS CD4 þ and CD8 þ T-cell isolation kits as per the manufacturer's instructions from 10 7 airway cells using LS columns. The purity of isolated CD4 þ or CD8 þ cells were analyzed by flow cytometry. To track cells, prior to transfer 5 mM Celltrace Violet dye (Invitrogen, Paisley, UK) was added to 10 6 cells, they were incubated with gentle agitation, washed, and resuspended in sterile PBS. Cytokine detection. Cytokine responses in the airway and lung cells after transfer and RSV infection were analyzed using a TH1/TH2 Group 1 Bio-Plex Pro Mouse Cytokine Assay Kit (Bio Rad, Watford, UK) according to the manufacturer's instructions.
Statistical analysis. Calculations as described in figure legends were performed using Prism 6 (GraphPad Software, La Jolla, CA).
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